Profile Picture
Rewards
  • Search
  • Chat
  • Images
  • Videos
  • Maps
  • News
  • Shopping
  • More
    • Flights
    • Travel
    • Hotels
    • Real Estate
    • My Bing
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Politics
  • Business

Trending on Bing

Fourth presidential debate
Enters transfer portal
Woman killed in shark attack
'Leave me alone'
Addresses Perry's death
Announces run for governor
Canceled after 3 seasons
Married in Mexico?
Out of hospital, back in prison
Takes aim at De Niro
WH warns Congress
Selling videos on Cameo
US factory orders drop
4 killed in Dallas shooting
Reveals plan to retire
5 family members shot dead
Makes runway debut
Exits presidential race
Historic $82 million deal
Announces 2024 tour
Dozens killed in Tanzania
To hear bankruptcy case
Skips window appearance
Ex-US ambassador arrested
Finishes at No. 1 for 8th time
Deadly Bronx apartment fire
ENEC, TerraPower deal
Mazdzer sets luge retirement
CO2 emissions increase
Makes fifth NFL appearance
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent
3,680 results
hrexecutive
4d
As anti-obesity drug prices soar, how employers can navigate difficult choices
High prices for anti-obesity drugs known as GLP-1 medications, coupled with high employee demand, are giving employers a lot ...
The Messenger on MSN3d
Pfizer Suffers Setback in Weight Loss Trial After Patients Drop Pill Due to Uncomfortable Side Effects
While Wegovy, Ozempic and Zepbound soar, other weight loss medications are struggling.
Reuters4d
Maker of Wegovy, Ozempic showers money on U.S. obesity doctors
Dr. Lee Kaplan took the stage with an urgent message, telling fellow physicians they have a powerful weapon to fight the ...
6don MSN
Mounjaro is more effective than Ozempic for weight loss in overweight and obese adults, real-world study says
Patients on Eli Lilly's Mounjaro were more likely to lose weight and experienced larger reductions in body weight compared to ...
3mon
Wegovy weight-loss drugmaker sees profits soar
The maker of weight-loss jabs Wegovy and Ozempic, Danish pharmaceutical giant Novo Nordisk, has reported a sharp rise in ...
Futurism2mon
Snack Food CEO Vows to Battle Ozempic
As the popularity of appetite-suppressing drugs like Ozempic and Wegovy continues to skyrocket, one of America's chief snack food overlords is readying himself — and his company's delicious ...
Healthline20d
Black People Are Facing Greater Challenges Accessing Anti-Obesity Drugs Like Ozempic and Wegovy
Share on Pinterest Diabetes and obesity disproportionately impact Black people, yet they are facing greater challenges gaining access to GLP-1 medications like Ozempic that could help treat these ...
Medindia19d
Medications and their Potential to Cause Increase 'Throat sore'
This section presents medications that are known to potentially lead to 'Throat sore' as a side effect." It's important to note that mild side effects are quite common with medications. Please be ...
Hosted on MSN1mon
Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?
Is the fervor over Ozempic just a passing fad? It doesn't appear to be the case after Novo Nordisk (NYSE: NVO) announced its results for the first nine months of 2023 on Thursday morning.
The Guardian1mon
Sales soar at Danish firm behind weight-loss drug semaglutide
Novo Nordisk says it struggling to keep up with demand after becoming Europe’s most valuable company The maker of blockbuster weight-loss drug semaglutide has reported a steep rise in sales and ...
BBC3mon
Wegovy weight-loss drugmaker sees profits soar
The maker of weight-loss jabs Wegovy and Ozempic, Danish pharmaceutical giant Novo Nordisk, has reported a sharp rise in profits on the back of surging demand for the drugs. Net profits were 39 ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
© 2023 Microsoft
  • Get the Bing App
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices